Detailed Narrative
Q1 FY20 Performance Overview
Suven Life Sciences reported a Q1 FY20 with flat revenue YoY, showing a marginal 1% growth. Despite this, profitability saw significant improvement, with EBITDA increasing by 40% and Net Profit by 47% compared to the same quarter last year. The management attributed this to a favorable product mix with higher-value products, including strong performance from commercial CRAMS.
CRAMS and Specialty Chemicals Business Outlook
The Specialty Chemicals segment achieved Rs. 100.53 crore in turnover for Q1 FY20, with a full-year guidance of Rs. 215-230 crore, representing 5-10% growth. Total CRAMS revenue was Rs. 91.77 crore, including Rs. 35.39 crore from commercial CRAMS. The full-year commercial CRAMS guidance was revised upwards to Rs. 160-180 crore, nearly doubling last year's Rs. 80 crore. Overall CRAMS business is projected to grow by 15% for the current financial year, with normal CRAMS growth at 10-15% and base CRAMS at 5-10%.
CAPEX and Capacity Expansion
The company plans a total CAPEX of Rs. 310 crore, with Rs. 220 crore allocated for intermediates and Rs. 90 crore for formulations. One intermediates block is expected to be fully operational by the end of FY20, with the second block and the formulations facility becoming operational by mid-to-end of FY21. These expansions are driven by new customer requirements and additional capacity needs, with investments expected to be recovered within a couple of years depending on product mix.
Rising Pharma Acquisition Strategy
Suven invested $35 million for a 25% stake in Rising Pharma, valuing the company at $140 million. The acquisition includes working capital and covers liabilities to vendors, with no debt. Management aims to restore Rising Pharma's valuation to its 2016 level of $450 million within 2-4 years, driven by CRAMS revenue from ANDA development, manufacturing, supply, and profit sharing from new ANDAs. Rising Pharma has over 100 ANDAs and a strong distribution network.
NCE Pipeline Update
Top-line data for SUVN-502 is now expected by the end of September or early October 2019, following delays in data collection. The Phase 2 study for SUVN-G3031 has received US FDA permission, with patient randomization starting this month, and data expected by August next year. Two other compounds, SUVN-D4010 and SUVN-911, are progressing well and are expected to be ready for Phase-II proof of concept within the next 4-6 months. The company maintains 82 molecules in Phase-I, 32 in Phase-II, 1 in Phase-III, and 4 commercial.
ANDA Pipeline and Formulation Business
Suven has 12 ANDAs under preparation, with 4 already filed and another 2 expected to be filed before the end of the year. The company anticipates receiving 4 ANDA approvals for commercialization in 2020-2021 and plans to file 3-5 ANDAs annually. The Rs. 90 crore formulation facility is expected to be ready by mid-next year, aligning with anticipated ANDA approvals. The focus is on niche, smaller ANDAs, with initial costs for the facility being higher but future additions expected to be more cost-effective.